Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Search inclusion criteria included studies describing either the incidence of HK events and any associated risk factors, or associations between HK or serum potassium concentration and adverse clinical outcomes including mortality, hospitalisation, major adverse cardiac events (MACE) and renin-angiotensin-aldosterone system inhibitors (RAASi) discontinuation in adult patients with chronic kidney disease (CKD), heart failure (HF), type 2 diabetes (T2DM) or hypertension.
|
31532067 |
2020 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of dual renin-angiotensin system (RAS) inhibition in heart failure (HF) is still controversial.
|
31814505 |
2020 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
|
31512149 |
2020 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection fraction.
|
31786973 |
2020 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin-angiotensin-aldosterone system inhibitors (RAASIs).
|
31119681 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments.
|
30836981 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
|
31493202 |
2019 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of PDE9 had a negligible effect on circulating hormones at the lower doses, but post-high dose, acutely increased renin activity (Normal: p < 0.001; HF: p < 0.05), vasopressin (Normal: p < 0.001; HF: p < 0.01), and cyclic adenosine monophosphate (HF: p < 0.001).
|
31416533 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
While targeting the renin-angiotensin-aldosterone system is currently used as the standard line of therapy for heart failure, there has been increased interest in inhibiting the transforming growth factor-β signaling pathway due its established role in cardiac fibrosis.
|
30930180 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has been previously documented that overactivation of the renin angiotensin system (RAS) is involved in HF pathophysiological mechanism.
|
31629013 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the efficacy of medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers has not been defined in TRC.
|
30859381 |
2019 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, in HF, the increases in renal norepinephrine spillover and plasma renin activity are augmented compared with the increase in RSNA.
|
31241978 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system inhibitors (RAASi) are now a standard treatment in most patients with cardiovascular disease, especially in those with heart failure (HF).
|
31800079 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elderly heart failure with reduced ejection fraction patients (≥75 years) received significantly fewer beta-blockers (77.8% vs. 84.2%), renin-angiotensin system inhibitors (75.2% vs. 89.7%), mineralocorticoid receptor antagonists (50.6% vs. 59.6%) and ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared to patients aged less than 60 years (<i>P</i><sub>for all trends</sub> < 0.01).
|
30866680 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elderly, patients with chronic kidney disease (CKD) and patients with heart failure who continue using renin-angiotensin-aldosterone-system (RAAS) inhibitors, diuretics, or non-steroidal-anti-inflammatory drugs (NSAIDs) during times of fluid loss have a high risk of developing complications like acute kidney injury (AKI).
|
31801476 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery.
|
30367208 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease.
|
31370961 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
|
31537750 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associated factors of HRV included advanced CKD, diabetes mellitus, serum albumin, severe proteinuria, Beck Anxiety Inventory score, erythropoietin use, renin-angiotensin system inhibitors and heart failure.
|
30328166 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant subset of patients with heart failure (HF) experience small to moderate rise in serum creatinine (RSC) in the setting of otherwise beneficial therapies such as aggressive diuresis or renin-angiotensin-aldosterone system (RAAS) inhibition.
|
31216531 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that Angs of the alternative renin-angiotensin system seem to play a role in HF with preserved ejection fraction and are linked to outcome in patients with HF and preserved ejection fraction.
|
31230551 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Canine renal sympathetic denervation prevents myocardial malignant remodeling by lowering the activity of the systemic sympathetic nerve and inhibiting renin-angiotensin-aldosterone system (RASS) activation, providing a new target and method for the treatment of heart failure.
|
31127792 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Medical therapy of heart failure including renin-angiotensin-aldosterone system inhibition and β-adrenergic blockade can blunt these deleterious processes.
|
31300181 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibitors of the renin-angiotensin-aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF).
|
31118203 |
2019 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Modulation of renin activity in experimental HF significantly reduces edema formation and the progression of systolic dysfunction and improves survival.
|
31261774 |
2019 |